7RM1

Antibody 2F2 in complex with P. vivax CSP peptide EDGAGNQPGANGAGNQPGANGAGNQPG

7RM1 の概要

• エントリーDOI: 10.2210/pdb7rm1/pdb
• 分子名称: 2E10.E9 Fab heavy chain, 2E10.E9 Fab light chain, peptide from Circumsporozoite protein variant VK247 (3 entities in total)
• 機能のキーワード: antibody, malaria, plasmodium vivax, circumsporozoite protein, antimicrobial protein
• 由来する生物種: Mus musculus (mouse); 詳細
• タンパク質・核酸の鎖数: 5
• 化学式量合計: 98688.87

構造登録者

Kucharska, I.,Ivanochko, D.,Julien, J.P. (登録日: 2021-07-26, 公開日: 2022-01-26, 最終更新日: 2024-10-23)

主引用文献

Kucharska, I.,Hossain, L.,Ivanochko, D.,Yang, Q.,Rubinstein, J.L.,Pomes, R.,Julien, J.P.
Structural basis of Plasmodium vivax inhibition by antibodies binding to the circumsporozoite protein repeats.
Elife, 11:-, 2022

PubMed Abstract: Malaria is a global health burden, with (Pf) and (Pv) responsible for the majority of infections worldwide. Circumsporozoite protein (CSP) is the most abundant protein on the surface of sporozoites, and antibodies targeting the central repeat region of CSP can prevent parasite infection. Although much has been uncovered about the molecular basis of antibody recognition of the PfCSP repeats, data remains scarce for PvCSP. Here, we performed molecular dynamics simulations for peptides comprising the PvCSP repeats from strains VK210 and VK247 to reveal how the PvCSP central repeats are highly disordered, with minor propensities to adopt turn conformations. Next, we solved eight crystal structures to unveil the interactions of two inhibitory monoclonal antibodies (mAbs), 2F2 and 2E10.E9, with PvCSP repeats. Both antibodies can accommodate subtle sequence variances in the repeat motifs and recognize largely coiled peptide conformations that also contain isolated turns. Our structural studies uncover various degrees of Fab-Fab homotypic interactions upon recognition of the PvCSP central repeats by these two inhibitory mAbs, similar to potent mAbs against PfCSP. These findings augment our understanding of host interactions and contribute molecular details of Pv inhibition by mAbs to unlock structure-based engineering of PvCSP-based vaccines.

PubMed: 35023832
DOI: 10.7554/eLife.72908

実験手法

X-RAY DIFFRACTION (3.19 Å)